PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Busulfan

Drugs in development · updated 30 October 2026

Busulfan: clinical trials and development status

Other names and codes: Busulfex, Myleran, Busilvex

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 9 July 2003

As of 30 October 2026 Busulfan is in 83 active clinical trials (recruiting or ongoing, phases I–III) for 90 diseases. The most advanced phase is III.

83Active trials
IIIMost advanced phase
90Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Busulfan and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 90 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Acute myeloid leukemiaIII35NCT05457556
Myelodysplastic SyndromesIII23NCT05457556
Precursor lymphoblastic lymphoma/leukemiaIII15NCT05457556
LeukemiaIII7NCT04547049
Acute biphenotypic leukaemiaIII5NCT05457556
Chronic myelomonocytic leukemiaII–III5NCT04708054
NeoplasmIII3NCT05477589
NeuroblastomaIII2NCT03126916
Residual neoplasmIII2NCT02724163
Thrombocythemia, EssentialIII2NCT06079879
GanglioneuroblastomaIII1NCT03126916
Graft-versus-host diseaseII8NCT00544115
Hematologic neoplasmII8NCT07524530
Myeloproliferative disordersII8NCT05564390
Hematologic DiseasesII5NCT04859946
Hodgkin lymphomaII5NCT02861417
LymphomaII5NCT07524530
MyelofibrosisII5NCT07228624
Non-Hodgkin lymphomaII5NCT02861417
Chronic granulomatous diseaseI–II4NCT05463133
Immunologic Deficiency SyndromesII4NCT01176006
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveII4NCT06001385
Lymphoproliferative disordersII4NCT04339777
Multiple myelomaII4NCT06207799
Myelodysplastic–myeloproliferative diseasesII4NCT07228624
Accelerated phase chronic myelogenous leukemiaII3NCT02727803
Burkitt lymphomaII3NCT03779854
Chronic lymphocytic leukemiaII3NCT06001385
Immune System DiseasesII3NCT04339777
Lymphoid leukemiaII3NCT03970096

Everything on Busulfan

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch